Literature DB >> 26183373

Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats.

Jessica E McDonald1,2, Julie A Kiland1, Paul L Kaufman1,3, Ellison Bentley2,3, N Matthew Ellinwood4, Gillian J McLellan1,2,3.   

Abstract

OBJECTIVE: To determine the effects of latanoprost on intraocular pressure (IOP) and pupil diameter (PD) in cats with inherited primary congenital glaucoma (PCG) and normal cats. ANIMALS STUDIED AND PROCEDURES: IOP and PD were measured in both eyes (OU) of 12 adult cats (six normal, six PCG), three times per week for 3 weeks prior to, for 3 weeks during, and for 2 weeks following twice-daily treatment with 0.005% latanoprost to the right eye (OD) and vehicle to the left (control) eye (OS). IOP and PD were measured hourly, for 8 h, 1 day prior to, and on the first and last days of treatment. Aqueous humor flow rate (AHF) was determined at baseline and at the end of the treatment phase in six normal cats.
RESULTS: Mean IOP was significantly lower in treated vs. control eyes of PCG cats, for up to 8 h following a single latanoprost treatment, and a maximal IOP reduction of 63% occurred in treated eyes at 3 h. Latanoprost acutely lowered IOP in cats with PCG, but this effect appeared to diminish over 3 weeks of treatment. AHF was modestly increased in the treated eyes of normal cats after 3 weeks of latanoprost treatment, although IOP was not significantly affected. Latanoprost caused miosis, with rebound mydriasis at 24 h posttreatment, in the treated eyes of all cats.
CONCLUSIONS: Further research is needed to determine the suitability and efficacy of latanoprost treatment for long-term IOP-lowering in cats with PCG or other forms of glaucoma.
© 2015 American College of Veterinary Ophthalmologists.

Entities:  

Keywords:  aqueous humor flow; cat; glaucoma; intraocular pressure; latanoprost; pupil diameter

Mesh:

Substances:

Year:  2015        PMID: 26183373      PMCID: PMC4755930          DOI: 10.1111/vop.12292

Source DB:  PubMed          Journal:  Vet Ophthalmol        ISSN: 1463-5216            Impact factor:   1.644


  48 in total

1.  Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal dogs.

Authors:  P E Miller; M J Nelson; S L Rhaesa
Journal:  Am J Vet Res       Date:  1996-01       Impact factor: 1.156

2.  Effects of prostaglandin F(2alpha)and carbachol on MAP kinases, cytosolic phospholipase A(2)and arachidonic acid release in cat iris sphincter smooth muscle cells.

Authors:  S Husain; A A Abdel-Latif
Journal:  Exp Eye Res       Date:  2001-05       Impact factor: 3.467

3.  Effect of reproductive status on intraocular pressure in cats.

Authors:  Ron Ofri; Nuriel Shub; Zvi Galin; Mordechai Shemesh; Laurence S Shore
Journal:  Am J Vet Res       Date:  2002-02       Impact factor: 1.156

4.  Intraocular pressure measurements obtained as part of a comprehensive geriatric health examination from cats seven years of age or older.

Authors:  M M Kroll; P E Miller; I Rodan
Journal:  J Am Vet Med Assoc       Date:  2001-11-15       Impact factor: 1.936

5.  The effect of dorzolamide 2% on circadian intraocular pressure in cats with primary congenital glaucoma.

Authors:  Kelly J Sigle; Gabriel Camaño-Garcia; Alicia L Carriquiry; Daniel M Betts; Markus H Kuehn; Gillian J McLellan
Journal:  Vet Ophthalmol       Date:  2011-09       Impact factor: 1.644

Review 6.  Feline glaucomas.

Authors:  Ursula Dietrich
Journal:  Clin Tech Small Anim Pract       Date:  2005-05

7.  Validation of the TonoVet® rebound tonometer in normal and glaucomatous cats.

Authors:  Gillian J McLellan; Jeremy P Kemmerling; Julie A Kiland
Journal:  Vet Ophthalmol       Date:  2012-06-06       Impact factor: 1.644

8.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

9.  Prostanoid-induced relaxation of precontracted cat ciliary muscle is mediated by EP2 and DP receptors.

Authors:  J Chen; D F Woodward
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-10       Impact factor: 4.799

10.  Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.

Authors:  Yasutaka Takagi; Tadashi Nakajima; Atsushi Shimazaki; Masaaki Kageyama; Takeshi Matsugi; Yasushi Matsumura; B'Ann T Gabelt; Paul L Kaufman; Hideaki Hara
Journal:  Exp Eye Res       Date:  2004-04       Impact factor: 3.467

View more
  5 in total

1.  Effects of topical corticosteroid administration on intraocular pressure in normal and glaucomatous cats.

Authors:  Allyson A Gosling; Julie A Kiland; Lauren E Rutkowski; Adam Hoefs; Norman Matthew Ellinwood; Gillian J McLellan
Journal:  Vet Ophthalmol       Date:  2016-02-15       Impact factor: 1.644

2.  Intraocular pressure with rebound tonometry and effects of topical intraocular pressure reducing medications in guinea pigs.

Authors:  Yue Di; Xiu-Mei Luo; Tong Qiao; Na Lu
Journal:  Int J Ophthalmol       Date:  2017-02-18       Impact factor: 1.779

3.  Effect of timolol maleate gel-forming solution on intraocular pressure, pupil diameter, and heart rate in normal and glaucomatous cats.

Authors:  Julie A Kiland; Andrea M Voss; Gillian J McLellan
Journal:  Vet Ophthalmol       Date:  2016-03-18       Impact factor: 1.644

Review 4.  Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma.

Authors:  Ryan G Strickland; Mary Anne Garner; Alecia K Gross; Christopher A Girkin
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

5.  Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.

Authors:  Tamara Kralj; Antonio Kokot; Mirna Zlatar; Sanja Masnec; Katarina Kasnik Kovac; Marija Milkovic Perisa; Lovorka Batelja Vuletic; Ana Giljanovic; Sanja Strbe; Suncana Sikiric; Slaven Balog; Bojan Sontacchi; Dijana Sontacchi; Matko Buljan; Eva Lovric; Alenka Boban Blagaic; Anita Skrtic; Sven Seiwerth; Predrag Sikiric
Journal:  Biomedicines       Date:  2021-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.